microtiter wells. Such samples must be diluted and reanalyzed.
mgfL, which approximates the 75th percentile in adults, are considered to be too high (2). The Consensus Panel recommended that all adults should be advised of their cholesterol concentration and counseled for follow-up and treatment as appropriate.
The Panel suggested that a patient's cholesterol evaluation would be most feasibly done during routine physician visits, but it also recommended study of the feasibility of other screening methods. Interest in mass screening has also been stimulated by the recent development of compact analytical systems in which plasma or serum cholesterol can be quickly measured in a small amount of blood. These analytical systems are portable, easily operated by persons lacking extensive laboratory training, and usable in physicians' offices or field sites. We will report separately the results of a collaborative study undertaken by the Lipid Research Clinics (LRCs) to develop and evaluate cholesterol screening strategies. In that study, the screening consisted of cholesterol measurements made in capillary blood samples with the Reflotron analyzer (Boehringer Mannheim Diagnostics, Indianapolis, IN). Here we report an evaluation of the accuracy and precision of the Reflotron compared with measurements made with standardized (3) laboratory methods.
Materials and Methods

Study Design
The screening method for cholesterol measurement was evaluated in four LRC centers. In two of them (The Johns Hopkins University, Baltimore, MD, and Washington University, St. Louis, MO) the analyses were performed in LRC patients during their routine visits. One center (University of Minnesota, Minneapolis, MN) screened participants as part of its Fargo-Moorhead Heart Health Program, and the other (Northwest Lipid Research Clinic, Seattle, WA) screened employees of the Boeing Company. At each location, the study was designed to evaluate the screening method as it would ordinarily be used, comparing cholesterol measurements in capillary blood samples analyzed with the Reflotron with those in venipuncture blood samples analyzed in laboratories.
Subject Sampling
We obtained blood samples from each subject by venipuncture and by fingerstick. The venipuncture blood sampies were drawn into evacuated blood-collection tubes containing sufficient disodium EDTA to give a final concentration of 1.5 mg/mL. Plasma was separated within 3 h and stored at 4#{176}C before analysis (4). We took the capillary blood sample from the finger and analyzed it within about 5 mm (see below).
Cholesterol Measurement
Venipancture samples. We measured plasma cholesterol concentrations in duplicate, using ftiliy enzymatic methods. Three of the laboratories used automatic analyzers. The Baltimore laboratory also used the latter reagent, in a semiautomated procedure: sample and reagent volumes were measured with an automatic pipet, and absorbances were measured with a spectrophotometer equipped with a flowthrough cell. Here, for succinctness, we refer to these methods as the "laboratory methods."
All of the laboratory methods were standardized according to the criteria of the Centers for Disease Control (CDC)-National Heart, Lung and Blood Institute Cholesterol Standardization Program. These criteria require that cholesterol measurements be accurate to within 3% of CDC-determined reference values and have coefficients of variation (CV) of 3% at cholesterol concentrations >1500 mgfL (3). As judged from the analysis of common qualitycontrol pools, cholesterol measurements in the four laboratories were comparable (see Results) .
Capillary blood samples. Using the Refiotron method according to the manufacturer's directions, we measured cholesterol in two sequential capillary blood samples from each subject. We calibrated the instruments with magnetic strips provided by the manufacturer. The data coded on these strips were used to set the incubation conditions and to convert instrument readings into units of concentration. We applied the sample (30 pL of whole blood taken into a heparinized tube for capillary-blood collection) to the test strip, allowed it to absorb into the sample application zone, and inserted the strip into the instrument no later than 15 s after the sample's initial application.
In the Reflotron, the blood sample is absorbed through a glass fiber filter layer, which removes the cells. The heparinized plasma then moves into a zone impregnated with the reagents and enzymes necessary for the measurement. After 175 s, the instrument measures the reflectance of the sample and converts this into concentration units, which are displayed on the instrument's digital readout.
The enzymic reactions used for the Reflotron method are similar to those used for the laboratory methods. Cholesteryl esters are first hydrolyzed. This reaction is catalyzed by cholesteryl esterase (EC 3.1.1.13). The unesterified cholesterol produced is then oxidized by cholesterol oxidase (EC 1.1.3.6) catalysis. One of the reaction products, hydrogen peroxide, is measured by use of a reaction in which a colored product is formed. The color is measured with the reflectance photometer.
Cont rol pools. Two lyophilized control pools (Precinorm U and Precipath U, both from Boehringer-Mannheim Diagnostics) were provided for use with the screening method. We reconstituted these pools with water according to the manufacturer's instructions.
In three of the laboratories, these pools were analyzed in duplicate in each analytical run with both the laboratory and screening methods. In the fourth laboratory, these pools were analyzed with the screening method only. The measurements were used to compare the laboratory methods with each other and with the screening measurements.
Results
We originally intended to use a single lot of test strips for all of the Reflotron analyses. It became apparent, however, that the calibration of the initial test strips was not based on CDC standardization criteria (3,6). The studies in two of the laboratories (Seattle and Minneapolis) were completed before this problem was recognized. The manufacturer then provided a new lot of test strips in which the calibration was based on the CDC Reference Method. The latter test strips were used in the other two laboratories. Here we report the results with both lots of strips. The calibration influenced the accuracy but not the precision of the screening method.
The average values we obtained with the laboratory methods for the lyophilized control pool with the lower cholesterol concentration (Table 1 ) differed by 0.5%; those for the pool with the higher concentration differed by 2.6%. The cholesterol measurements were therefore similar in the three laboratories in which these pools were analyzed with the laboratory methods. Table 2 indicates the results we obtained for subjects' samples. In the St. Louis and Baltimore laboratories, the Reflotron cholesterol values averaged 0.8% and 3.5% lower, respectively, than those obtained with the laboratory methods. In both cases, CDC-referenced test strips were used, and in both centers the group mean cholesterol concentrations for the subjects were about 2500 mgIL. The group standarddeviations obtained with the Reflotron and laboratory methods were virtually identical. In the Minneapolis and Seattle laboratories, the Reflotron values were 3.7% and 7.8% lower than the laboratory values. The mean cholesterol concentration in these subjects was about 2000 mg/L, and the group standard deviations obtained with the Reflotron method were lower than those determined with the laboratory methods. Table 3 shows the parameters for the linear-regression equations that describe the relationships between the screening and laboratory methods in each of the four centers. The coefficients of correlation ranged from 0.92 to 0.96. The regression equations for the Baltimore and St. Louis laboratories, in which CDC-referenced test strips were used, predict a negative bias of 0% to -3% for the Reflotron method in the concentration range 2000 to 2400 mg/L (2). There were, however, fairly large discrepancies between the screening and laboratory methods in some samples. Among the laboratories, the difference between the two methods exceeded 300 mgfL, or about 12%, in 5% to 15% of the samples.
In Table 4 we compare the analyses for samples in which the differences were >300 mgfL with those for samples that agreed more closely. In three of the laboratories, both screening measurements were made with a single instrument; in the fourth, two different instruments were used. The samples for which the laboratory and screeningvalues 
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Cholesterol 2400 mg/I. (Tables 6 and 7 ). The paired differences between the two methods ranged from about 0% to -4% for both subgroups of samples in the laboratories that used recalibrated test strips ( Table 6 ). The Reflotron method had negative biases of approximately 7% and 11% for samples with cholesterol concentrations above 2400 mg/L, compared with 3% and 7% for samples with concentrations <2400 mgfL (Table 6) in the laboratories in which the original test strips were used, however. Table 7 shows the parameters for the linear-regression equations relating the Reflotron and laboratory methods for the two subgroups of samples. The equations predict that the Reflotron values would be 1% to 3% lower than the laboratory values in the concentration range 2400 to 3000 mg/L, and 1% to 4% lower in the concentration range 2000 to 2390 mg/L in the two laboratories that used the recalibrated test strips. The coefficients of correlation between the two methods were about the same (r = 0.88 to 0.94) in both subgroups of samples (Table 7) . In contrast, in the two laboratories that used the original test strips, the equations predict negative biases of 5% to 14% in the concentration range 2400 to 3000 mg/L and 3% to 7% in the concentration range 2000 to 2390 mgfL, and the coefficients of correlation between the Reflotron and laboratory methods were low (r = 0.59, 0.76) for samples with cholesterol concentrations >2400 mg/L. The precision of the screening method was assessed for subjects' samples by examining the absolute difference between the first and second screening measurement. The difference between duplicates ranged from 2.0% to 4.3% for the screening method, and 0.7% to 2.6% for the laboratory methods (Table 8) true duplicates, because both analyses were done on aliquots of the same plasma. For the screening measurements, however, the two samples were taken sequentially, and we considered that they might not be equivalent. Table  9 shows the first and second screening values in the three centers in which the measurements were made with a single instrument. The first value tended to be about 1% higher than the second value. In one laboratory, the difference was not statistically significant, and in the other two laboratories it was only marginally significant.
We also examined the relative precision of the screening method when operated by different operators using different Refiotron instruments.
This evaluation was performed in the three centers in which the replicate screening analyses were made with a single instrument. A total of 10 operators used eight instruments, and we examined 11 different instrument-operator combinations. In all cases except one, the average difference between duplicates for the different operator-instrument combinations ranged from 1.8% to 3.9%. The difference was 5.4% for the final instrument-operator combination. Thus, although the screening method was less precise than the laboratory methods, we judged its precision to be adequate for screening purposes.
Finally, we examined the sensitivity and specificity of the screening procedure, using the laboratory methods for reference.
We defined the sensitivity of the screening method as the proportion of subjects in whom the cholesterol concentrations were correctly identified as exceeding 2000 mgfL as confirmed by measurements in venipuncture samples using the laboratory methods. This is the currently used cutpoint between desirable and borderline-high cholesterol concentrations (2). The specificity was defined as how accurately the screening method identified subjects whose cholesterol concentrations were <2000 mg/L.
The sensitivities of the cholesterol measurements were 0.93 and 0.99 in the Baltimore and St. Louis centers, respectively, with specificities of 0.93 and 0.80 in the two locations (Table 10) 
Discussion
In this study we evaluated the Refiotron method for total plasma cholesterol measurement, using CDC-standardized laboratory methods as the point of reference. The screening method had a slight negative bias which, on average, was greater in the two laboratories in which the originally calibrated test strips were used.
The screening method was also precise. The average difference between duplicates was <4% in all of the centers except Minnesota, where the replicate screening measurements were made with different instruments. Even in this latter case, the average agreement between duplicates was 4.3%. The coefficients of correlation between the screening method and laboratory values ranged from 0.92 to 0.96. In some samples, however, the screening and laboratory values differed by over 12%, exceeding the bias expected on the basis of the analysis of the quality-control pools. In all of these cases, however, the duplicate measurements with both methods agreed well, indicating that the differences we observed between the Reflotron and laboratory values did not result from random errors.
The reason for the large differences in some of the samples is not clear. Although the samples for which poor agreement was observed tended to have higher cholesterol concentrations, there was no consistent relationship between the correspondence of values or the coefficients of correlation for the two methods, and cholesterol concentration per se. One possibility is that in some cases the cholesterol concentration of the capillary sample actually differed from that of the venipuncture sample. This might result from postural changes, the time that elapsed between the samplings if both samples were not obtained at samples (7,8) , although in a previous unpublished study in the Johns Hopkins laboratory, we found an average difference of 0.45% in 70 sample pairs in which the same cholesterol method was used for both measurements. Another possibility is that the Refiotron and laboratory methods might have been influenced differently by non-cholesterol constituents of the sample matrix, because any interfering substances would have been diluted 100-fold by the reagent used for the laboratory method.
These findings notwithstanding, the accuracy and precision of the screening method was encouraging, particularly when one considers the conditions under which the method was operated. In the Seattle and Minnesota centers, the instruments were moved to the field for on-site screening, and in the Baltimore and St. Louis centers they were located in clinics and operated during the normal course of clinic activities. In addition, the screening analyses were performed primarily by nurses or other paramedical personnel who had no special laboratory training, and we made no attempt to modify the procedure or improve its performance during the course of the study.
We conclude that the screening method is a potentially useful tool for large-scale cholesterol screening. Our findings suggest that, in a normal population, screening measurements calibrated to the CDC Reference Method would detect about 95% of the individuals with plasma cholesterol concentrations >2000 mgfL. However, several points should be mentioned.
First, the fact that the test strips are calibrated by the manufacturer is at once a strength and potential weakness of the Reflotron method. The use of a manufacturer-calibrated system effectively allows a common reference point for diverse users. This approach was used by the Lipid Research Clinics Program (4), in which all the laboratories were provided with aliquots of the same cholesterol standard solutions. In those studies, the within-laboratory components of variation of the cholesterol analyses exceeded the between-laboratory component by approximately 4 to 1 (9, 10). The strength of this approach, however, is tempered by the consequencesof miscalibration during manufacture. The user cannot readily recalibrate the test strips, and there is a potential for generating a large number of inaccurate results. The manufacturer, therefore, assumes considerable responsibility for providing accurately calibrated test strips.
Second, the Refiotron procedure is easy to operate and does not require a long period of training or experience. Even so, operators must be instructed in proper sampling and analysis procedures and should be made aware of points in the procedure where errors can occur. For example, with the Refiotron method, the operator must place the blood sample on the test strip and insert the strip into the instrument within about 15 s. To prevent sample splashing during handling, however, the operator must be careful to ensure that it is completely absorbed into the test strip before the strip is inserted into the instrument.
Finally, the method is so easy to operate that one can easily overlook the need for periodic instrument maintenance and quality control. Nevertheless, whether the instrument is used in a physician's office or for on-site screening, the recommended cleaning and other maintenance procedures should be performed, and a formal quality-control system should be established to monitor continuously the accuracy and precision of the screening analyses.These concerns would be minimized if the analyses are performed by qualified technologists.
